{"id":"dsp-5423p-active-to-flex","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5095026","moleculeType":"Small molecule","molecularWeight":"419.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug acts as a partial agonist at the dopamine D1 receptor, which plays a key role in motor control, motivation, and cognitive function. By selectively activating D1 receptors, DSP-5423P aims to provide therapeutic benefit while minimizing the side effects associated with full dopamine agonism. The 'Active-to-Flex' designation suggests a flexible dosing or formulation approach to optimize therapeutic outcomes.","oneSentence":"DSP-5423P is a selective dopamine D1 receptor partial agonist designed to modulate dopaminergic signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:03.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (in development)"}]},"trialDetails":[{"nctId":"NCT02287584","phase":"PHASE3","title":"Confirmatory Study of DSP-5423P in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2014-12","conditions":"Schizophrenia","enrollment":580}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DSP-5423P Active-to-Flex","genericName":"DSP-5423P Active-to-Flex","companyName":"Sumitomo Pharma Co., Ltd.","companyId":"sumitomo-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DSP-5423P is a selective dopamine D1 receptor partial agonist designed to modulate dopaminergic signaling in the central nervous system. Used for Parkinson's disease (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}